$12MSeries A, 28 April 2026
Series A to advance lead drug LHP588 in its Phase 2 SPRING trial.
- Amount
- $12M
- Stage
- Series A
- Announced
- 28 April 2026
- Lead
- Double Point Ventures
- Use of funds
- Series A to advance lead drug LHP588 in its Phase 2 SPRING trial.
- Checked
- Announced by the company
- Sources
- Lighthouse Pharmaceuticals raises $12M Series A for Alzheimer's biospace.com
Lighthouse Pharmaceuticals raises $12M Series A for Alzheimer's pulse2.com